newsfilter
← Latest News
GlobeNewswire·

Zealand Pharma Announces Financial Results for the First Half of 2026

ZEAL
  • Zealand Pharma announced financial results for the first half of 2026, reporting revenue of DKK 4,525 million & a net profit of DKK 3,524 million.
  • The company decided to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results showing double-digit weight loss with a tolerability profile comparable to placebo.
  • Boehringer Ingelheim presented positive Phase 3 results for survodutide in the SYNCHRONIZE-1 & SYNCHRONIZE-MASLD trials, demonstrating up to 16.6% weight loss & liver fat normalization.
  • Zealand Pharma initiated a Phase 1b clinical trial for ZP9830, a Kv1.3 ion channel blocker, in patients with psoriasis to establish proof-of-concept for autoimmune diseases.
  • The company launched a USD 200 million share buyback program & entered a USD 100 million royalty monetization agreement with Royalty Pharma for rusfertide.
  • Camilla Sylvest & Iris Löw-Friedrich were elected to the Board of Directors to support the company's scaling into a generational biotech.
  • Financial guidance for 2026 remains unchanged with expected collaboration revenue of DKK 4.5 billion & operating expenses between DKK 2.7-3.3 billion.
  • Upcoming H2 2026 milestones include initiating Phase 3 petrelintide trials, reporting ZUPREME-2 topline data, & submitting a resubmitted NDA for dasiglucagon to the FDA.
  • Zealand Pharma ranked as the most attractive employer in the Danish Life Science sector according to the 2026 Medwatch Image Report.